"Designing Growth Strategies is in our DNA"
Coronary artery disease is characterized by a condition in which the coronary arteries of the heart is clogged by the buildup of fatty acids and cholesterol. This plaque formation is usually called atherosclerosis. Some of the major symptoms of coronary artery disease include chest pain, stable angina, ischemia among others. The major factors causing coronary artery disease comprise of diabetes, high cholesterol, high blood pressure, excessive consumption of alcohol, and smoking among others.
Current treatment of coronary artery disease includes angioplasty, coronary artery bypass grafting, stent implantation, lifestyle modifications, and drugs. Therapeutic drugs, for instance, beta blockers, antiplatelet drugs, statins are prescribed for the treatment of coronary artery disease. Making changes to the diet to lower blood cholesterol level and exercising is one of the primary factors to control heart disease.
Research organization and pharmaceutical companies are working in collaboration to discover effective treatment methods for coronary artery disease. The treatment options studies include devices as well as therapeutic drugs. For instance, AZD5718 is a drug being developed by AstraZeneca is currently in Phase 2 clinical trial.
To know how our report can help streamline your business, Speak to Analyst
Currently, around 45% of the clinical trials are in Phase 2 stage. Approximately 70% of the clinical trials are being conducted by government institutes and research organizations.
The report on ‘Coronary Artery Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for coronary artery disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Coronary Artery Disease.
The report on ‘Coronary Artery Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.